These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36375766)

  • 1. Biomimetic lung-on-a-chip to model virus infection and drug evaluation.
    Tan J; Guo Q; Tian L; Pei Z; Li D; Wu M; Zhang J; Gao X
    Eur J Pharm Sci; 2023 Jan; 180():106329. PubMed ID: 36375766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A High-Throughput, High-Containment Human Primary Epithelial Airway Organ-on-Chip Platform for SARS-CoV-2 Therapeutic Screening.
    Fisher CR; Mba Medie F; Luu RJ; Gaibler RB; Mulhern TJ; Miller CR; Zhang CJ; Rubio LD; Marr EE; Vijayakumar V; Gabriel EP; Lopez Quezada L; Zhang CH; Anderson KS; Jorgensen WL; Alladina JW; Medoff BD; Borenstein JT; Gard AL
    Cells; 2023 Nov; 12(22):. PubMed ID: 37998374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microfluidic Organs-on-a-Chip for Modeling Human Infectious Diseases.
    Wang Y; Wang P; Qin J
    Acc Chem Res; 2021 Sep; 54(18):3550-3562. PubMed ID: 34459199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future perspective: high-throughput construction of new ultrasensitive cytokine and virion liquid chips for high-throughput screening (HTS) of anti-inflammatory drugs or clinical diagnosis and treatment of inflammatory diseases.
    Feng Y; Huang J; Qu C; Huang M; Chen Z; Tang D; Xu Z; Wang B; Chen Z
    Anal Bioanal Chem; 2020 Nov; 412(28):7685-7699. PubMed ID: 32870351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering organ-on-a-chip systems to model viral infections.
    Shahabipour F; Satta S; Mahmoodi M; Sun A; de Barros NR; Li S; Hsiai T; Ashammakhi N
    Biofabrication; 2023 Feb; 15(2):. PubMed ID: 35390777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The breathtaking world of human respiratory in vitro models: Investigating lung diseases and infections in 3D models, organoids, and lung-on-chip.
    Dichtl S; Posch W; Wilflingseder D
    Eur J Immunol; 2024 Mar; 54(3):e2250356. PubMed ID: 38361030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
    Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
    J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
    Krishna G; Pillai VS; Veettil MV
    Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
    Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J
    J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral activity and mechanism of the antifungal drug, anidulafungin, suggesting its potential to promote treatment of viral diseases.
    Shen S; Zhang Y; Yin Z; Zhu Q; Zhang J; Wang T; Fang Y; Wu X; Bai Y; Dai S; Liu X; Jin J; Tang S; Liu J; Wang M; Guo Y; Deng F
    BMC Med; 2022 Oct; 20(1):359. PubMed ID: 36266654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically Relevant Influenza Virus Evolution Reconstituted in a Human Lung Airway-on-a-Chip.
    Si L; Bai H; Oh CY; Jin L; Prantil-Baun R; Ingber DE
    Microbiol Spectr; 2021 Oct; 9(2):e0025721. PubMed ID: 34523991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomimetic Human Disease Model of SARS-CoV-2-Induced Lung Injury and Immune Responses on Organ Chip System.
    Zhang M; Wang P; Luo R; Wang Y; Li Z; Guo Y; Yao Y; Li M; Tao T; Chen W; Han J; Liu H; Cui K; Zhang X; Zheng Y; Qin J
    Adv Sci (Weinh); 2021 Feb; 8(3):2002928. PubMed ID: 33173719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2.
    Plante KS; Dwivedi V; Plante JA; Fernandez D; Mirchandani D; Bopp N; Aguilar PV; Park JG; Tamayo PP; Delgado J; Shivanna V; Torrelles JB; Martinez-Sobrido L; Matos R; Weaver SC; Sastry KJ; Newman RA
    Biomed Pharmacother; 2021 Jun; 138():111457. PubMed ID: 33721754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection.
    Sohn SY; Hearing J; Mugavero J; Kirillov V; Gorbunova E; Helminiak L; Mishra S; Mackow E; Hearing P; Reich NC; Kim HK
    mBio; 2021 Dec; 12(6):e0275621. PubMed ID: 34724828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of resveratrol against emerging respiratory viral infections.
    Filardo S; Di Pietro M; Mastromarino P; Sessa R
    Pharmacol Ther; 2020 Oct; 214():107613. PubMed ID: 32562826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study.
    Mondal M; Sarkar C; Jamaddar S; Khalipha ABR; Islam MT; Mahafzah A; Mubarak MS
    Infect Disord Drug Targets; 2021; 21(7):e160921188777. PubMed ID: 33292147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.